Comparative Pharmacology
Head-to-head clinical analysis: RAU SED versus RAUDIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAU SED versus RAUDIXIN.
RAU-SED vs RAUDIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
None Documented
None Documented
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Category C
Category C
Antihypertensive
Antihypertensive